Mechanistically, endometrial cancer activates the pathway through either CTNNB1 exon 3 mutations, which prevent β-catenin degradation via phosphorylation, or Adenomatous Polyposis Coli protein (APC) inactivation, which disrupts the degradation complex [26]. Here, APC is linked to endometrial cancer.